PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up study

Title: 70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up of a prospective multicenter cohort study Publication: Breast Cancer Research and Treatment 2024 Authors: Eline E. F. Verreck, Anne Kuijer, Julia E. C. van Steenhoven, José H. Volders, Annette W. G. van der Velden, Read More

Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients

Publication: Heliyon 10 (2024) e39485 Authors: Daniele Generali, Andrea Rocca, Carla Strina, Manuela Milani, Enrico Fiorino Valeria Cervoni, Carlo Azzini, Antonella Saracino, Ingnazio Ciliberto, Nicoletta Ziglioli, Marzia Alberio, Fabiola Giudici, Martina Dester, Oriana Ciani, Giulia Fornaro, Sergio Aguggini, Christa Dreezen, Darina Pronin, Stefanie Ende Title:  Assessing the long-term prognostic Read More

MammaPrint Genomic Assay Providing Prognostic Information in Early Breast Cancer: 10-Year Follow-Up From a Retrospective German Breast Cancer Registry Analysis

Publication: EMJ Oncol. 2024;12[1]:138-147. Authors: C. Jackisch, D. Pronin, Christa Dreezen, T. Dimpfl, R. Büttner, G. Kunz, C. Langwieder, M. Rees, K. Lerchl Title: MammaPrint Genomic Assay Providing Prognostic Information in Early Breast Cancer: 10-Year Follow-Up From a Retrospective German Breast Cancer Registry Analysis Abstract INTRODUCTION: Gene expression assays, Read More

Identification of Racial Disparities (ESMO 2024)

Publication: ESMO 2024 Authors: Sonya Reid, M.D., Jennifer G. Whisenant, Ph.D.; Jennifer Wei, M.D., Ph.D., Harshini Ramaswamy, M.Sc., Nicole Stivers, Ph.D., Andrea Menicucci, Ph.D., William Audeh, M.D., Tuya Pal, M.D. Title: Identification of racial disparities across MammaPrint® and BluePrint® subtypes in HR+HER2- breast cancer Background: Black women in the Read More